Overview

Pemigatinib is a selective inhibitor of fibroblast growth factor receptors 1, 2 and 3 (FGFR1/2/3), and its role in bile-duct cancer is entirely defined by a biomarker. The agent is intended for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma carrying an FGFR2 fusion or rearrangement. Selecting the right patient therefore hinges on genomic testing rather than on anatomy or prior lines alone, making FGFR2 status the gateway to treatment.

Why FGFR2 Defines the Population

In intrahepatic cholangiocarcinoma (iCCA), FGFR2 gene fusions and rearrangements occur in a identifiable subset of patients — commonly cited in the range of roughly 10 to 16 percent of iCCA cases. These alterations drive constitutive FGFR signaling that sustains tumor cell proliferation. Because the drug targets that pathway, only tumors with an FGFR2 fusion or rearrangement are expected to benefit; testing separates a small, molecularly defined population from the broader cholangiocarcinoma group.

Confirming Eligibility by NGS

Eligibility is established with a validated next-generation sequencing assay performed on tumor tissue, which detects FGFR2 fusions and select rearrangements. An FDA-approved companion diagnostic (FoundationOne CDx) was authorized alongside pemigatinib, underscoring that biomarker confirmation is integral, not optional. Testing is typically pursued in advanced disease that has progressed after prior systemic therapy, aligning with the approved previously-treated population.

Dosing and Population Fit

Pemigatinib is supplied as 4.5 mg, 9 mg and 13.5 mg tablets, supporting individual dose selection within the approved schedule. The biomarker-defined population means procurement and formulary planning should track testing volumes rather than overall cholangiocarcinoma incidence, since only the fusion-positive subgroup consumes the agent. This precision-oncology logic concentrates demand in a narrow, identifiable patient set. Because eligibility hinges on genomic results, multidisciplinary review of sequencing findings typically precedes treatment initiation, and the staged dosing schedule supports tolerability monitoring during chronic use.

FAQ

Q: Which cholangiocarcinoma patients are eligible for pemigatinib? A: Previously treated, unresectable or metastatic cholangiocarcinoma with a confirmed FGFR2 fusion or rearrangement, most often intrahepatic disease.

Q: How is FGFR2 status confirmed? A: By validated next-generation sequencing of tumor tissue; an FDA-approved companion diagnostic was authorized with the drug.

Q: What proportion of iCCA carries FGFR2 alterations? A: FGFR2 fusions and rearrangements are reported in roughly 10 to 16 percent of intrahepatic cholangiocarcinoma cases.

Q: What strengths are available? A: The product is supplied as 4.5 mg, 9 mg and 13.5 mg tablets to support dose selection.